Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-31
2007-07-31
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S340000, C548S518000, C548S560000, C548S562000
Reexamination Certificate
active
10862844
ABSTRACT:
HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided.
REFERENCES:
patent: 3983140 (1976-09-01), Endo et al.
patent: 4049495 (1977-09-01), Endo et al.
patent: 4137322 (1979-01-01), Endo et al.
patent: 4198425 (1980-04-01), Mistui et al.
patent: 4255444 (1981-03-01), Oka et al.
patent: 4262013 (1981-04-01), Mistui et al.
patent: 4375475 (1983-03-01), Willard et al.
patent: 4681893 (1987-07-01), Roth
patent: 4851427 (1989-07-01), Wareing
patent: 5055484 (1991-10-01), Jendrall et al.
patent: 5091386 (1992-02-01), Kesseler et al.
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 6479490 (2002-11-01), Gong et al.
patent: 0221025 (1987-05-01), None
patent: WO 01/52829 (2001-07-01), None
patent: WO 2004/005250 (2004-01-01), None
Selling, H.A., et al. Acetylenic Sulfinamides: A Novel Class of Compounds, Synthietic Communications; 1976 ,6 (2), p. 129-134.
Babin,,P., et al. Electrophillic Properties of Sulphamyl Chloride. Application to the Synthesis of alpha beta-Acetylenic Sulphonamides; J. Chem Research 1982, 1, p. 16-17.
Baudin, J. B., et al, A Simpe and Effiecient Preparation of N,n-Disubstituted (1-Alkyne)- or (E)-(1-Alkene)sulfinamides and their Conversion into the Correspnding Sulfinates or Sulfonamides; Synlett, 11, 1992, pp. 911-913.
Hlasta, D. J., et al., Steric Effects on teh Regioselectivity of Azide-Alkyne Dipolar Cycloaddition Reaction: The Sysnthesis fo Humah Leukocyte Elastase Inhibitors; J. Organic Chem, 1994, 59, pp. 6184-6189.
Procopiou, P.A., et al, Inhibitors of Cholesterol Biosynthese 2. 3-5Dihydroxy-7-(N-pyrrolyl)-6-heptenoates, a Novel Series of HMG-CoA Reductase Inhibitors, J of Medical Chem., 1993, 36, pp. 3658-3662.
Ansell, J. et. al., hsCRP and HDL Effects of Statins Trial (CHEST): Rapid Effect of Statin Therapy on C-Reative Protein and High-Density Lipoprotein Levels; Heart Disease, 2003, 5, p. 2-7.
Beaird, S, et al., HMG-CoA Reductase Inhibitors: Assessing Differences in Drug Interactions and Safety Profiles; Journal of the American Pharmaceutical Assoc., 2004, vol. 40, No. 5, p. 637-644.
Lipid Research Clinics Program, The Lipid Research Clinics Corionary Primary Previention Trial Results; Journal of American Medical Assoc.,1984, vol.251, No. 3, p. 351-374.
Takemoto, M., et. al., Pleiotropic Effects of 3-Hyrdroxy-3-Methylglutaryl Coenzyme A. Redutase Inhibitors; Arterioscler Throm Vasc Biol., 2001, vol. 21, p. 1712-1713.
Bottorff, M., et. al., Long-term Safety of Hepatic Hydroxymethl Glutaryl Coenzyme a Reductase Inhibitors; Arch. Intern. Med, 2000, vol. 160, p. 2273-2280.
McTaggart, F., et. al., Preclinical and Clinical Pharmacology of Rosuvastation, a New-Hydroxy-3-Methylglutaryl Coenzyme A. Reductase Inhibitor; 2001 vol. 87 (suppl) p. 28B-32B.
Hulcher, F., et. al., Inhibition of Hepatic Cholesterol Biosynthesis by 3-5 Hydroxy-3,4,4-Trimethylvaleric Acid and Its Site of Action; Archives of Biochemistry and Biophyics 1971, vol. 146, p. 422-427.
Brown, M. et. al., Lowering Plasma Cholesterol by Raising LDL Receptors, New England Journal of Medicine, 1981, vol. 305, No. 9, p. 515-517.
Singer, F., et. al., New Inhibitors of in vitro Conversion of Acetate and Mevalonate to Cholesterol; Proc. Soc. Exper. Biol. Med., 1959, vol. 102, 370-373.
Brown, A., et al., Crystal and Molecular Structure of Compaction, a New Antifugal Metabolite fromPenicillium breviocmpactum; Journal of Chem. Soc. Perkin I, 1976, 1165-1170.
McKenney, J. et al, Pharmacologic Characteristics of Statins, Clin Cardiol, 2003, vol. 26 (suppl. III), pp. III-32-III-38.
Chapman, M. et al, Optimizing the pharmacology of statins: characteristics of rosuvastatin, Atherosclerosis Supplements 2, 2002, pp. 33-37.
Roth, B., et al, Inhibitors of Cholesterol Biosynthesis . . . ; Journal of Medicinal Chemistry, 1991, vol. 34, pp. 357-366.
Graul, A., et al, Atorvastatin Calcium Hypolipidemic HMG-CoA Reductase Inhibitor, Drugs of the Future, 1997, vol. 22, No. 9, pp. 956-968.
Jahng, Y., et al, Design of a new class of HMG-CoA reductase inhibitors, Drugs of the Future, 1995, vol. 20, No. 4, pp. 387-404.
Kennedy Robert Michael
Park William Keun-Chan
Roth Bruce David
Song Yuntao
Trivedi Bharat K.
Benson Gregg C.
Nardone Rona A.
Pfizer Inc.
Saeed Kamal A.
Shiao Rei-tsang
LandOfFree
Pyrrole-based HMG-CoA reductase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrole-based HMG-CoA reductase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrole-based HMG-CoA reductase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3822272